~~<i id='E50122C905'><strike id='E50122C905'><tt id='E50122C905'><pre id='E50122C905'></pre></tt></strike></i>~~

Home» knowledge» fashion

fashion

author：comprehensive 2025-08-15 04:19:06 Page View：18

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Are embryos people? Reproductive medicine's future depends on the answer
Next article： Tori Bowie and the unacceptable rates of Black maternal death

explore

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Doctor of U.S. President Joe Biden says he is fit for duty

EvanVucci/APBETHESDA,Md.—PresidentJoeBiden “continuestobefitforduty,”hisdoctorwroteWednesdayaftercon

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Adopting new red light myopia treatments may be short

AdobeMyopia,ornear-sightedness,isontherise:Nearlyhalfoftheworld’spopulationwillbenearsightedby2050,